Avanos Medical (NYSE: AVNS) is one of 28 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it contrast to its competitors? We will compare Avanos Medical to similar companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.
Volatility and Risk
Avanos Medical has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Avanos Medical’s competitors have a beta of 0.87, indicating that their average share price is 13% less volatile than the S&P 500.
Valuation and Earnings
This table compares Avanos Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Avanos Medical||$611.60 million||$79.30 million||27.73|
|Avanos Medical Competitors||$1.31 billion||$198.48 million||26.50|
Avanos Medical’s competitors have higher revenue and earnings than Avanos Medical. Avanos Medical is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Avanos Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Avanos Medical Competitors||-142.92%||-71.42%||-15.20%|
Insider and Institutional Ownership
90.7% of Avanos Medical shares are owned by institutional investors. Comparatively, 57.1% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 1.4% of Avanos Medical shares are owned by insiders. Comparatively, 9.9% of shares of all “Surgical appliances & supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Avanos Medical and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Avanos Medical Competitors||147||782||1386||71||2.58|
Avanos Medical presently has a consensus price target of $67.50, indicating a potential upside of 3.59%. As a group, “Surgical appliances & supplies” companies have a potential upside of 0.98%. Given Avanos Medical’s higher possible upside, equities analysts clearly believe Avanos Medical is more favorable than its competitors.
Avanos Medical beats its competitors on 7 of the 13 factors compared.
About Avanos Medical
Avanos Medical, Inc. operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management. Its products include post-operative pain management solutions, minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. This segment sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and other brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.